Aptamer Sciences Inc

KOSDAQ:A291650 Stock Report

Market Cap: ₩50.4b

Aptamer Sciences Balance Sheet Health

Financial Health criteria checks 6/6

Aptamer Sciences has a total shareholder equity of ₩13.0B and total debt of ₩8.6B, which brings its debt-to-equity ratio to 66.3%. Its total assets and total liabilities are ₩30.6B and ₩17.6B respectively.

Key information

66.3%

Debt to equity ratio

₩8.61b

Debt

Interest coverage ration/a
Cash₩21.58b
Equity₩12.99b
Total liabilities₩17.59b
Total assets₩30.58b

Recent financial health updates

Recent updates

Health Check: How Prudently Does Aptamer Sciences (KOSDAQ:291650) Use Debt?

Jul 26
Health Check: How Prudently Does Aptamer Sciences (KOSDAQ:291650) Use Debt?

Is Aptamer Sciences (KOSDAQ:291650) A Risky Investment?

Mar 26
Is Aptamer Sciences (KOSDAQ:291650) A Risky Investment?

Financial Position Analysis

Short Term Liabilities: A291650's short term assets (₩23.2B) exceed its short term liabilities (₩15.5B).

Long Term Liabilities: A291650's short term assets (₩23.2B) exceed its long term liabilities (₩2.1B).


Debt to Equity History and Analysis

Debt Level: A291650 has more cash than its total debt.

Reducing Debt: A291650 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A291650 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: A291650 has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 24.6% each year.


Discover healthy companies